CJC-1295 (no DAC) + Ipamorelin
CJC-1295 (no DAC) + Ipamorelin is a supplier-defined research blend of two growth hormone-axis peptides: CJC-1295 without DAC (Mod GRF 1-29), a GHRH analogue, and ipamorelin, a selective ghrelin-receptor agonist. It is commonly supplied as 5 mg + 5 mg. The two act at different receptors, but published data on the combination itself are limited to animal work, and it is not an approved product.
Last reviewed · Identity data matched to PubChem · 8 peer-reviewed sources
Key facts
- Contents: CJC-1295 without DAC (Mod GRF 1-29) and ipamorelin
- Commonly supplied as 5 mg + 5 mg or 10 mg + 10 mg per vial
- Pairs a GHRH analogue with a ghrelin receptor (GHS-R1a) agonist
- Component molecular weights: 3367.9 g/mol and 711.9 g/mol (PubChem)
- Direct combination data: one mouse muscle-loss finding reported in a 2026 review
- Supplier-defined blend; neither component is FDA approved; both are prohibited in sport
Chemical Identity
| Components | CJC-1295 without DAC (Mod GRF 1-29) + Ipamorelin |
|---|---|
| Compound type | Blend |
What Is the CJC-1295 (no DAC) + Ipamorelin Blend?
The CJC-1295 (no DAC) + Ipamorelin blend is a research formulation that combines two synthetic peptides in one vial: CJC-1295 without DAC, also called Mod GRF 1-29, and ipamorelin. The first is an analogue of growth hormone-releasing hormone (GHRH); the second is a growth hormone secretagogue. Suppliers commonly list it as 5 mg + 5 mg or 10 mg + 10 mg, and some listings give only a total content of 10 mg or 20 mg.
The combination is defined by suppliers, not by a regulator or pharmacopeia, so there is no standardized ratio or specification. The name can also be ambiguous. The peptide first published as CJC-1295 in 2005 was a tetrasubstituted human GRF(1-29) with an added maleimide-bearing lysine that binds serum albumin, the drug affinity complex (DAC).[1] The version in this blend lacks that extension.
The pairing is widely marketed. A 2026 sports medicine review selected CJC-1295 + ipamorelin as one of the most popular peptide therapies to evaluate for orthopaedic physicians.[2]
Components at a Glance
The blend contains one GHRH analogue and one ghrelin-receptor agonist, two peptides that differ greatly in size. Molecular weights below are PubChem values.
| Component | Class | Primary target or mechanism studied | Molecular weight |
|---|---|---|---|
| CJC-1295 without DAC (Mod GRF 1-29) | Synthetic GHRH analogue, 29 residues | GRF (GHRH) receptor on anterior pituitary cells, the target of human GRF(1-29) and its derivatives[1] | 3367.9 g/mol (C152H252N44O42) |
| Ipamorelin | Growth hormone secretagogue, pentapeptide | GHRP-like receptor, the growth hormone secretagogue receptor 1a (GHS-R1a)[3][4] | 711.9 g/mol (C38H49N9O5) |
Why These Compounds Are Studied Together
The two components act at different receptors in the growth hormone axis, which is the structural logic of the blend. Profiling with selective GHRP and GHRH antagonists showed that ipamorelin, like GHRP-6, releases growth hormone through a GHRP-like receptor rather than the GHRH receptor.[3] CJC-1295 without DAC is a modified human GRF(1-29), and GRF(1-29) derivatives act at the GRF receptor on anterior pituitary cells.[1]
Ipamorelin is also studied for its selectivity. In conscious swine, none of the secretagogues tested changed FSH, LH, prolactin or TSH. GHRP-6 and GHRP-2 raised ACTH and cortisol, but ipamorelin did not raise either to levels significantly different from those after GHRH stimulation.[3]
Published research on the specific combination is limited. A 2026 review reports that CJC-1295 combined with ipamorelin significantly improved maximum tetanic tension in mouse models of glucocorticoid-induced muscle loss, and stresses that the finding is limited to animal studies.[2] The review abstract does not state which form of CJC-1295 was used. Beyond this, the evidence comes from studies of the individual components, and the sources compiled here do not establish synergy between them. A 2026 doping review adds that most published peptide studies examine controlled therapeutic use, not the combined regimens common in bodybuilding.[5]
Because a blend must contain both peptides at their stated amounts, researchers typically verify each component with HPLC and mass spectrometry certificates of analysis.
Research Status
The blend is not an approved or standardized product, and neither component is approved by the US Food and Drug Administration for any indication. A 2026 review of growth hormone-axis peptides marketed as research compounds lists both CJC-1295 without DAC and ipamorelin, notes the absence of regulatory approval for physique- or performance-related uses, and highlights uncertainty about product composition and stacking practices in unregulated supply chains.[6]
Evidence quality is low. A 2026 scoping review covering CJC-1295 and ipamorelin found that 67% of identified musculoskeletal publications used preclinical animal models, and that human studies were few and mostly lacked robust controls.[7] GHRH analogues and growth hormone secretagogues are prohibited in sport under the World Anti-Doping Agency Prohibited List, and Danish customs seizures have contained glycine-modified analogues of both modified GRF 1-29 and ipamorelin.[8]
For laboratory use, the practical questions are identity and composition: whether both peptides are present at the stated amounts, and whether the CJC-1295 component is the no-DAC form, since the name alone does not distinguish them.
Commonly Supplied Research Formats
CJC-1295 (no DAC) + Ipamorelin is listed by 10 of the 11 major U.S. research-peptide suppliers we track. The most commonly listed formats are:
- 5/5mg
- 10mg
- 10/10mg
- 20mg
Supplier catalog survey, October 2026. Quantities refer to net peptide per vial as labeled.
Frequently Asked Questions
What is in the CJC-1295 + Ipamorelin blend?
The blend contains two synthetic peptides: CJC-1295 without DAC (Mod GRF 1-29), a 29-residue analogue of growth hormone-releasing hormone, and ipamorelin, a five-residue growth hormone secretagogue that acts at the ghrelin receptor. Suppliers commonly list it as 5 mg + 5 mg or 10 mg + 10 mg per vial. It is a supplier-defined combination, not a standardized or approved product.
Is CJC-1295 + Ipamorelin the same as CJC-1295 with DAC?
No. The CJC-1295 in this blend is the version without DAC, the modified GRF(1-29) peptide on its own. CJC-1295 with DAC carries an extra lysine bearing a maleimide group that binds serum albumin, which extended plasma persistence beyond 72 hours in rats. The two share a name but differ in structure and molecular weight, so listings should state which form is present.
Has the CJC-1295 + Ipamorelin combination been studied?
Only to a limited extent. A 2026 review reports that CJC-1295 combined with ipamorelin improved maximum tetanic tension in mice with glucocorticoid-induced muscle loss, a finding limited to animal studies. No controlled human trial of the combination appears in the sources reviewed for this page. Most of what is known comes from studies of ipamorelin and of GHRH analogues individually.
How do CJC-1295 and ipamorelin differ?
They target different receptors. CJC-1295 without DAC is a GHRH analogue based on human GRF(1-29), which acts at the GRF receptor on pituitary cells. Ipamorelin is a pentapeptide that releases growth hormone through the ghrelin receptor, GHS-R1a. Ipamorelin is also much smaller, at 711.9 g/mol versus 3367.9 g/mol, and in swine it did not raise ACTH or cortisol.
Is the CJC-1295 + Ipamorelin blend FDA approved?
No. Neither CJC-1295 without DAC nor ipamorelin is approved by the FDA for any indication, and the blend itself has no approval or standardized specification. Recent reviews describe both peptides as unregulated research compounds with uncertain product composition. Both also fall under classes prohibited in sport by the World Anti-Doping Agency.
References
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology 2005. PMID 15817669 · DOI
- Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American journal of sports medicine 2026. PMID 41476424 · DOI
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European journal of endocrinology 1998. PMID 9849822 · DOI
- Lu Z, Ngan MP, Liu JYH, et al. The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism. Physiology & behavior 2024. PMID 39043357 · DOI
- Coutinho LFD, DE Oliveira Neves LF, Camilo RP. A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. The Journal of sports medicine and physical fitness 2026. PMID 41880199 · DOI
- Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in endocrinology 2026. PMID 42395176 · DOI
- Tewari K, Liu TP, Im C, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. The American journal of sports medicine 2026. PMID 42578445 · DOI
- Gajda PM, Holm NB, Hoej LJ, et al. Glycine-modified growth hormone secretagogues identified in seized doping material. Drug testing and analysis 2019. PMID 30136411 · DOI
Related Compounds
This profile summarizes chemical data and peer-reviewed literature for educational and laboratory-research reference. It is not medical advice, and nothing here describes or recommends use in humans or animals. How we source and verify data.